BOSULIF vs TASIGNA

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. BOSULIF and TASIGNA are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	BOSULIF	TASIGNA
Rating	New	70/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	BOSUTINIB MONOHYDRATE	NILOTINIB HYDROCHLORIDE
Manufacturer	Pf Prism Cv	Novartis
Dosage forms	Capsule, Tablet	Capsule
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	Boxed warning
Treats	Bcr-Abl Positive Chronic Myelogenous Leukemia	Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia

bosulif tasigna

Rating

New

70/100

Pharmacy pays

—

Type

Active ingredient

BOSUTINIB MONOHYDRATE

NILOTINIB HYDROCHLORIDE

Manufacturer

Pf Prism Cv

Novartis

Dosage forms

Capsule, Tablet

Capsule

Drug class

Kinase Inhibitor

Boxed warning

None

Boxed warning

Treats

Bcr-Abl Positive Chronic Myelogenous Leukemia

Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia

Frequently asked questions

What is the difference between Bosulif and Tasigna?

Bosulif contains Bosutinib Monohydrate, while Tasigna contains Nilotinib Hydrochloride — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.